United Immunity raises $14M from ITOCHU for in vivo cancer cell therapy
What's the deal? United ImmunityDealroom has a profile for this one. Try Dealroom →, a Tokyo-based biotech, has raised US$16.9M (roughly $14 million) in a late-stage venture round led by ITOCHU CorporationDealroom has a profile for this one. Try Dealroom → via a private placement. The company develops therapies targeting intractable diseases, including cancer.
What's the endgame? United Immunity's proprietary Myeloid Targeting Platform delivers therapeutic agents to specific cells, including immune cells like macrophages and dendritic cells. It is using the technology to develop an in vivo CAR-macrophage therapy that turns the body's own immune cells into cancer-attacking cells.
Why now? Conventional immunotherapies and cell therapies still struggle with solid tumours — on efficacy, treatment resistance, side effects, and manufacturing costs. The Japan Agency for Medical Research and Development (AMED)Dealroom has a profile for this one. Try Dealroom → selected United Immunity for its startup ecosystem programme, V-eco.
Combined with the private funding, a V-eco grant of up to US$21.5M brings total project funding to as much as US$38.5M. United Immunity plans to use the money to accelerate global clinical development and bring new therapies into practice.
What's ITOCHU's angle? The trading house has named pharmaceuticals and healthcare a priority area. Beyond capital, it says it will supply materials, tap its network, and push collaboration with the pharmaceuticals and chemicals industries to support United Immunity's growth.
ITOCHU frames the deal within the Takaichi administration's growth strategy across 17 strategic fields, part of a broader public-private effort to back innovation and address unmet medical needs.
The signal: At roughly $14 million, this ranks among the larger late-stage venture rounds in Japanese health — sitting in the 95th percentile across 313 comparable deals all-time. The financing shows Japan's trading giants moving deeper into advanced drug development, pairing corporate capital with state grants to push homegrown biotech onto the global stage.
Image credit: United Immunity
